Group Jonas Nilsson

Research summary

Our research seek to identify biomarkers of response to new targeted therapies and immunotherapies. We are making personalized animal models, so called PDX models or Avatar mice. These are used to test drugs as well as further humanization for use in immune oncology research.

The research has generated the framework of starting the Sahlgrenska Translational Melanoma Group (SATMEG), consisting of basic researchers and clinical investigators working together to devise new therapies against melanoma.

Group members at SCCR

Lead:
Jonas Nilsson, PhD, Group leader at Sahlgrenska Center for Cancer Research and Professor of Experimental Cancer Surgery

Senior Research Fellows:
Lisa Nilsson, PhD, Senior staff scientist
Lars Ny, MD/PhD, Associate professor, oncologist
Samuel Alsén, PhD, Postdoctoral fellow
Rebecca Riise, PhD, Researcher

Post-graduate students:
Vasu Sah, PhD student

Technical staff:
Carina Karlsson, Biomedical Scientist
Sofia Stenqvist, Animal technician

Affiliated members:
Sahlgrenska Translational Melanoma Group (SATMEG)

Selected publications

1. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
   Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah V, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA. Nature communications, 2021, epub.
    
2. Molecular profiling of driver events in metastatic uveal melanoma.
   Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke GS, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir BO, Jespersen H, Ny L, Lindnér P, Larsson E, Olofsson Bagge R, Nilsson JA. Nature communications, 2020, 11:1894
    
3. Supporting clinical decision-making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.
   Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen J, Carstam L, Olofsson Bagge R, Nilsson LM, Nilsson JA. Annals of Oncology, 2020, 31:266-273
    
4. H-STS, L-STS, and KRJ-I are not authentic GEPNET cell lines.
   Hofving T, Karlsson J, Nilsson, O, Nilsson JA. Nature Genetics, 2019, 51:1426-1427
    
5. HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice.
   Forsberg EM, Lindberg MF, Jespersen H, Alsén S, Olofsson Bagge R, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA. Cancer Res. 2019
    
6. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
   Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA. Nature communications. 2017; 8(1):707. 
    
7. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
   Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(26):E2721-30.
    
8. Therapeutic implications for the induced levels of Chk1  in Myc-expressing cancer cells. Clinical cancer research.
   Höglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, Nikolova V, Keller U, Nilsson JA. Clin Cancer Res. 2011; 17(22):7067-79. 
    
9. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.
   Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. Blood. 2009; 113(18):4281-8.
    
10. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL. Cancer cell. 2005; 7(5):433-44.

More group Jonas Nilsson publications on PubMed